Advancing Global Health
Gilead recognizes that the development of innovative medicines for life-threatening diseases is only one aspect of improving public health. We also invest in programs that promote prevention, strengthen healthcare infrastructure, and provide education and financial support to the most vulnerable communities around the world.
By enabling access to medicines, challenging assumptions, fighting stigma and collaborating with partners worldwide, we work not simply to treat some of the world’s most challenging public health threats – but to eliminate them.
Keeping Girls and Young Women HIV-Free in Sub-Saharan Countries
Gilead partners with the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) to help reduce HIV in adolescent girls and young women in 10 sub-Saharan African countries.
Gilead and WHO Tackle VL in Southeast Asia
Visceral leishmaniasis (VL) is a parasitic disease. An estimated 50,000 to 90,000 new cases occur worldwide each year, but it is estimated that only 25 to 45% of those cases are reported1. VL is almost always fatal if untreated. We are collaborating with the World Health Organization (WHO) to provide our treatment free of charge to all people diagnosed with the disease.